Kyverna Therapeutics Prices 13.33M Shares at $7.50, Raising Approximately $100M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Source: Newsfilter
- Public Offering Pricing: Kyverna Therapeutics has priced an underwritten public offering of 13,333,333 shares at $7.50 each, expected to raise approximately $100 million, thereby enhancing its financial capacity in the autoimmune disease sector.
- Underwriter Selection: The offering is managed by J.P. Morgan, Leerink Partners, Morgan Stanley, and Wells Fargo Securities, reflecting strong market confidence in the company's future growth prospects.
- Transaction Timeline: The offering is anticipated to close on or about December 18, 2025, subject to customary closing conditions, ensuring timely access to funds to support clinical development initiatives.
- Registration Statement Validity: The securities are offered under an effective S-3 registration statement, indicating the company's thorough compliance preparations, which may bolster investor confidence in the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KYTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KYTX
Wall Street analysts forecast KYTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KYTX is 29.50 USD with a low forecast of 20.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.210
Low
20.00
Averages
29.50
High
33.00
Current: 8.210
Low
20.00
Averages
29.50
High
33.00
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
- M&A Surge: In 2025, small and mid-cap biopharma companies accounted for 57% of acquisitions by deal count, with 33 deals totaling $30.9 billion, indicating a significant recovery in market confidence despite a drop in median deal value from $516 million to $303 million.
- Shift in Investor Focus: Investor attention has shifted from GLP-1 obesity drugs to cancer and autoimmune disease treatments in 2025, particularly next-generation cell therapies, reflecting strong demand for innovative treatment options and potential growth opportunities in the biotech sector.
- Strong Clinical Data: Approximately $6 billion in acquisitions related to next-generation cell therapies occurred over the past six months, highlighting significant interest from big pharma in this niche, which could drive stock price increases for involved companies.
- Optimistic Outlook: Analysts expect increased M&A and strategic partnerships in 2026, particularly in immunology and rare diseases, with a lower interest rate environment improving funding conditions and further supporting the growth of biotech companies.
Continue Reading
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
- Drug Trial Failure: Biohaven Ltd announced that its depression drug BHV-7000 failed to significantly reduce depressive symptoms in a six-week clinical trial, causing shares to plummet 14.3% to $9.27 in pre-market trading, reflecting a substantial decline in market confidence regarding its R&D capabilities.
- Severe Market Reaction: The news of the trial's failure triggered panic among investors, leading to a rapid decline in Biohaven's stock price during pre-market trading, indicating the high sensitivity of the biopharmaceutical sector to clinical outcomes, which may impact the company's future financing and R&D plans.
- Increased Competitive Pressure: With Biohaven's drug trial failure, market attention shifts to other competitors, particularly in the depression treatment space, potentially leading investors to reassess the market outlook and investment value of related companies.
- Wider Industry Implications: Biohaven's failure could have a ripple effect across the biopharmaceutical industry, particularly in terms of R&D investments and clinical trial designs, prompting other companies to more cautiously evaluate their drug development strategies.
Continue Reading